c-Kit, a type III receptor tyrosine kinase (RTK), plays a crucial role in cancer occurrence. Currently, c-Kit is mainly considered a stem cell factor (SCF), which participates in vital functions of the human body, such as fertility, homeostasis, and melanogenesis; nevertheless, early studies on c-Kit introduced it as an oncogene. Deregulation of c-Kit, including overexpression and gain of function mutations, has been detected in several human cancers. Leukemia is the first cancer linked to c-Kit activating mutation. c-Kit, a protooncogene in a region on the long arm of chromosome 4 (4q11–4q13), encodes the SCF receptor (CD117). c-Kit also plays an important role in stem cell maintenance and differentiation. Numerous Kit mutation sites are found and vary in different cancer types,16 reflecting the effect of each mutation on downstream signaling pathways including PI3K, Src kinase and Ras-Erk. Kinase superfamily proteins are considered a main target for molecular cancer therapy, so the use of kinase inhibitors could significantly improve cancer treatment.


1.Maryam Abbaspour Babaei,et al. Drug Des Devel Ther. 2016; 10: 2443–2459.